KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated DepreciationAssetsBuildingsCash & EquivalentsCommon EquityConstruction in ProgressCurrent Deferred RevenueDividends payablesLand & ImprovementsLiabilities and Shareholders EquityLoans - NetLoans - NetMinority InterestOther Non-Current AssetsPayablesProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - AccuredReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

National Health Investors (NHI) Cash & Equivalents (2016 - 2026)

National Health Investors filings provide 18 years of Cash & Equivalents readings, the most recent being $24.9 million for Q1 2026.

  • On a quarterly basis, Cash & Equivalents fell 81.52% to $24.9 million in Q1 2026 year-over-year; TTM through Mar 2026 was $24.9 million, a 81.52% decrease, with the full-year FY2025 number at $19.6 million, down 19.21% from a year prior.
  • Cash & Equivalents hit $24.9 million in Q1 2026 for National Health Investors, up from $19.6 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $135.0 million in Q1 2025 to a low of $11.4 million in Q1 2024.
  • Median Cash & Equivalents over the past 5 years was $19.6 million (2025), compared with a mean of $32.0 million.
  • Biggest five-year swings in Cash & Equivalents: soared 1088.73% in 2025 and later tumbled 81.52% in 2026.
  • National Health Investors' Cash & Equivalents stood at $19.3 million in 2022, then increased by 15.84% to $22.3 million in 2023, then rose by 8.69% to $24.3 million in 2024, then dropped by 19.21% to $19.6 million in 2025, then rose by 27.13% to $24.9 million in 2026.
  • The last three reported values for Cash & Equivalents were $24.9 million (Q1 2026), $19.6 million (Q4 2025), and $81.6 million (Q3 2025) per Business Quant data.